EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer


Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.

Related Videos
Video 11 - "Treating Patients With RCC Who Progress Following Adjuvant Therapy"
Video 10 - "RCC: Informing Treatment Decisions with Clinical Trial Data"
Video 9 - "KEYNOTE-564: Adjuvant Pembrolizumab in Renal Cell Carcinoma"
Related Content